• Map.All coronavirus outbreaks in Spain

At least until September it will not be known whether one of the most promising vaccines for coronavirus - that of the University of Oxford - will be effective or not. However, in the final phase of clinical trials, the researchers involved in its development announce a very encouraging finding. Apparently, it could provide "double protection" against SARS-CoV-2 , more than expected.

According to the analyzed blood samples of the volunteers, this immunization generates a response against the virus not only through the stimulation of antibodies, but also of T lymphocytes, "killer cells" that act against the infection. This sum of shields is the one that is expected to be able to protect the people of the Covid-19.

Although the data is important, there is still a way to go until you are sure that this formula works effectively. It is not even known what the duration of this supposed protection offered by the vaccine would be.

It is one of the most advanced candidates, among more than 140 that are being studied worldwide. The goal is to end this pandemic, which continues to spread and which has already infected nearly 14 million people and killed at least 587,000.

At the moment, you cannot set dates for the vaccine, "things could go wrong, but the reality is that by working with a large pharmaceutical company [AstraZeneca], this vaccine could be available in September," according to David Carpenter, president of the Berkshire Research Ethics Committee, which approved the Oxford trial and continues to work with this group of scientists.

This project is being developed at the University of Oxford, with funding from the United Kingdom government and with the collaboration of the pharmaceutical company AstraZeneca, for the global manufacture and distribution of the vaccine in development, so that it can be rapidly and massively available in case of success. Although it cannot yet be said that this injectable is effective, the signed agreement is to supply around two billion doses worldwide.

This immunization is currently in phase three of the clinical trials, targeting 4,000 volunteers in the United Kingdom, to which another 10,000 will be added, and in Brazil it is already being tested in 5,000 participants. Efficacy results are expected in the fall.

It is a weakened version of the common cold that causes chimpanzee infections. According to the scientists, "it generates a strong immune response with a single dose and it is not a virus that replicates," so "it cannot cause continuous infection in the vaccinated individual." It also contains the genetic material of the spike protein of SARS-CoV-2, the coronavirus strain that causes Covid-19 disease.

In Carpenter's words, if the vaccine works, it will first "be administered to the most vulnerable, such as the elderly and health workers."

For his part, the British Minister of Health, Matt Hancock, has indicated that the researchers, among whom there is also a team from Imperial College London, are working to achieve the "best scenario" that makes it possible to circulate a vaccine throughout This year, although he has admitted that this is more likely to happen in 2021. "We are all working to achieve the best of scenarios, we are all giving AstraZeneca and the team at Oxford and Imperial (College London) all possible support. We are also working on other potential vaccines worldwide, including America, Germany, and the Netherlands. "

According to the criteria of The Trust Project

Know more

  • Science and health
  • Coronavirus
  • Covid 19
  • China

SaludCovid-19, the risk of getting it at home reaches almost 20%

Health "I have seen health professionals cry: cry of helplessness, cry of exhaustion"

ChinaLi-Meng Yan's Way of the Cross, the virologist who uncovered China's secrets about Covid-19

See links of interest

  • News
  • Translator
  • Programming
  • Calendar
  • Horoscope
  • Classification
  • League calendar
  • Films
  • Cut notes
  • Themes
  • Coronavirus
  • Eibar - Real Valladolid
  • Real Madrid - Villarreal, live
  • Athletic Club - Leganés
  • Barcelona - Osasuna
  • Celta de Vigo - Levante